A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business Overview Biodesix, Inc. (“Biodesix”, “we,” “us,” “our” or the “Company”) is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics. We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Biodesix Development Services (Development Services) providing diagnostic testing services and consulting to biopharmaceutical, life sciences, and diagnostic companies. During 2025, we achieved numerous company milestones: •We delivered on our commercial and diagnostic services strengths resulting in an estimated $88.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 88M | 88M | 71M | 49M | 38M | 55M |
| Net Income | -35M | -35M | -43M | -52M | -65M | -43M |
| EPS | $-4.67 | $-4.67 | $-132.80 | $-12.80 | $-31.00 | $-31.60 |
| Free Cash Flow | -24M | -24M | -52M | -46M | -48M | -30M |
| ROIC | -42.8% | -69.0% | -74.9% | -131.0% | -143.5% | -145.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -29.56 | 2.97 | 13.26 | 1.55 | 0.51 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -28M | -28M | -34M | -41M | -51M | -41M |
| Operating Margin | -31.5% | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% |
| ROE | 0.0% | -383.1% | -205.6% | -1138.6% | -317.6% | -218.8% |
| Shares Outstanding | 8M | 8M | 0M | 4M | 5M | 4M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 25M | 46M | 55M | 38M | 49M | 71M | 88M | 88M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 10M | 11M | 13M | 13M | 10.0M | 9.6M | 12M | 12M |
| SG&A | 31M | 35M | 51M | 61M | 67M | 80M | 88M | 88M |
| EBIT | -27M | -23M | -41M | -51M | -41M | -34M | -28M | -28M |
| Op. Margin | -108.9% | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% | -31.5% |
| Net Income | N/A | -31M | -43M | -65M | -52M | -43M | -35M | -35M |
| Net Margin | N/A | -68.8% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% | -39.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -54.9% | -145.2% | -143.5% | -131.0% | -74.9% | -69.0% | -42.8% |
| ROE | N/A | -76.2% | -218.8% | -317.6% | -1138.6% | -205.6% | -383.1% | 0.0% |
| ROA | N/A | -25.9% | -56.7% | -70.4% | -52.6% | -44.1% | -38.2% | -40.3% |
| Cash Flow | ||||||||
| Op. Cash Flow | -22M | -21M | -28M | -45M | -23M | -49M | -23M | -23M |
| Free Cash Flow | -23M | -23M | -30M | -48M | -46M | -52M | -24M | -24M |
| Owner Earnings | -25M | -28M | -36M | -55M | -32M | -61M | -33M | -33M |
| CapEx | 1.3M | 1.9M | 2.2M | 3.3M | 23M | 3.2M | 259K | 259K |
| Maint. CapEx | 2.8M | 2.9M | 3.2M | 3.6M | 3.3M | 5.8M | 5.7M | 5.7M |
| Growth CapEx | 0 | 0 | 0 | 0 | 20M | 0 | 0 | 0 |
| D&A | 2.8M | 2.9M | 3.2M | 3.6M | 3.3M | 5.8M | 5.7M | 5.7M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 170K | 3.7M | 4.9M | 6.0M | 5.4M | 6.6M | 4.1M | 4.1M |
| Debt Repayment | 0 | 0 | 45M | 29M | 49K | 51K | 21K | 21K |
| Balance Sheet | ||||||||
| Net Debt | 25M | -85M | -55M | -54M | 8.2M | 9.5M | 35M | 54M |
| Cash & Equiv. | 5.3M | 62M | 33M | 43M | 26M | 26M | 19M | 19M |
| Long-Term Debt | 24M | 16M | 10.0M | 25M | 35M | 36M | 47M | 47M |
| Debt/Equity | -0.16 | 0.96 | 0.51 | 1.55 | 13.26 | 2.97 | -29.56 | 0.00 |
| Interest Coverage | -8.9 | -3.0 | -9.1 | -6.3 | -4.3 | -4.2 | -3.6 | -3.6 |
| Equity | -225M | 41M | 20M | 21M | 4.6M | 21M | -2.5M | -2.5M |
| Total Assets | 45M | 121M | 76M | 93M | 99M | 97M | 87M | 87M |
| Total Liabilities | 270M | 80M | 56M | 72M | 95M | 76M | 90M | 90M |
| Intangibles | 15M | 13M | 12M | 9.8M | 7.9M | 5.9M | 3.9M | 3.9M |
| Retained Earnings | -227M | -259M | -302M | -367M | -420M | -462M | -498M | -498M |
| Working Capital | -9.9M | 54M | 15M | 30M | 6.3M | 25M | 15M | 15M |
| Current Assets | 13M | 86M | 44M | 53M | 40M | 39M | 33M | 33M |
| Current Liabilities | 23M | 32M | 29M | 23M | 33M | 14M | 17M | 17M |
| Per Share Data | ||||||||
| EPS | -2,539.40 | -129.60 | -31.60 | -31.00 | -12.80 | -132.80 | -4.67 | -4.67 |
| Owner EPS | -18.58 | -17.87 | -9.32 | -11.25 | -7.75 | -188.88 | -4.38 | -4.38 |
| Book Value | -169.42 | 26.30 | 5.06 | 4.25 | 1.12 | 64.58 | -0.33 | -0.33 |
| Cash Flow/Share | -16.35 | -13.65 | -7.24 | -9.28 | -5.61 | -150.49 | -3.08 | -3.92 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.3M | 1.6M | 3.9M | 4.8M | 4.1M | 0.3M | 7.6M | 7.6M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 14.4 | 16.4 | 8.5 | 33.8 | 9.2 | N/A | N/A |
| Price/Sales | N/A | 10.5 | 19.5 | 5.3 | 2.7 | 2.9 | 0.9 | 1.0 |
| FCF Yield | N/A | -3.9% | -9.4% | -27.7% | -29.6% | -27.1% | -45.7% | -25.7% |
| Market Cap | N/A | 591M | 324M | 174M | 155M | 191M | 52M | 92M |
| Avg. Price | N/A | 306.01 | 271.97 | 41.58 | 32.60 | 31.66 | 10.66 | 12.14 |
| Year-End Price | N/A | 377.60 | 83.00 | 36.00 | 38.00 | 29.60 | 6.82 | 12.14 |
BIODESIX INC passes 0 of 9 quality checks, indicating weak fundamentals.
BIODESIX INC (BDSX) has a 5-year average return on invested capital (ROIC) of -112.7%. This is below average and may indicate limited pricing power.
BIODESIX INC (BDSX) has a market capitalization of $92M. It is classified as a small-cap stock.
BIODESIX INC (BDSX) does not currently pay a regular dividend.
BIODESIX INC (BDSX) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
BIODESIX INC (BDSX) reported annual revenue of $88 million in its most recent fiscal year, based on SEC EDGAR filings.
BIODESIX INC (BDSX) has a net profit margin of -39.8%. The company is currently unprofitable.
BIODESIX INC (BDSX) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BIODESIX INC (BDSX) reported earnings per share (EPS) of $-4.67 in its most recent fiscal year.
BIODESIX INC (BDSX) has a return on equity (ROE) of -383.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for BIODESIX INC (BDSX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIODESIX INC (BDSX) has a book value per share of $-0.33, based on its most recent annual SEC filing.